Predictors of Facial Pain and Headache Associated With Cryotherapy Ablation of the Posterior Nasal Nerve for the Treatment of Chronic Rhinitis.
| Autor: | Razmi SE; School of Engineering Medicine, Texas A&M (Agricultural and Mechanical) College of Medicine, Houston, USA., Dhanda AK; Department of Otolaryngology - Head and Neck Surgery, Houston Methodist Hospital, Houston, USA., Shenoi J; School of Engineering Medicine, Texas A&M (Agricultural and Mechanical) College of Medicine, Houston, USA., Khan F; School of Engineering Medicine, Texas A&M (Agricultural and Mechanical) College of Medicine, Houston, USA., Takashima M; Department of Otolaryngology - Head and Neck Surgery, Houston Methodist Hospital, Houston, USA., Ahmed OG; Department of Otolaryngology - Head and Neck Surgery, Houston Methodist Hospital, Houston, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Jun 05; Vol. 16 (6), pp. e61749. Date of Electronic Publication: 2024 Jun 05 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.61749 |
| Abstrakt: | Objective: Cryotherapy ablation of the posterior nasal nerve (PNN) for treatment of patients with refractory chronic rhinitis (CR) is associated with postoperative facial pain and headache. This study sought to understand factors that may contribute to the development of this adverse effect. Methods: Patients undergoing PNN cryotherapy ablation for refractory CR at a single institution from January 2018 to August 2023 were included. Demographics and clinical characteristics were collected via chart review and interview. Student's T-test and Chi-square tests were used to assess the significance of quantitative and categorical data, respectively (alpha = 0.05). Results: Forty-eight patients underwent cryotherapy ablation. Twenty-eight patients (58%) reported having facial pain and headache (adverse effect group) immediately post-procedurally. The average age of the adverse effect group was 54.9 years (SD: 17.8 years) which was significantly lower (p=0.002) than the asymptomatic group (69.7 years, SD: 8.7 years). Female patients were significantly more likely to experience this adverse event than males (p=0.04). Moreover, Caucasian females were significantly more likely to experience this adverse effect when compared to all patients experiencing the adverse effect (n=15, p=0.04). Previous diagnosis of migraine disorder was more common in the adverse effect group (28%) compared to the asymptomatic group (15%) but not statistically significant (p=0.26). Previous migraine, trigeminal neuralgia, or headache disorder diagnoses were not significantly correlated with adverse effect prevalence (p = 0.26, 0.24, 0.15, respectively). Conclusion: Given the relative immediacy and severity of this adverse effect, physicians should strongly consider these factors when counseling and selecting certain patient groups for this procedure. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Institutional Review Board, Houston Methodist Hospital issued approval #PRO00034032. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: Masayoshi Takashima declare(s) personal fees from Acclarent. Masayoshi Takashima declare(s) personal fees from LivaNova. Omar G. Ahmed, Masayoshi Takashima declare(s) personal fees from Aerin Medical . Omar G. Ahmed, Masayoshi Takashima declare(s) personal fees from Medtronic. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Razmi et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|